Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (6): 1075-1078.doi: 10.3969/j.issn.1673-8225.2011.06.027

Previous Articles     Next Articles

TAp63 gene expression in bone marrow mononuclear cells derived from acute lymphoblastic leukemia patients

Pan Yang-qiong1, Liu Yan-fang1, 2, Sun Hui1, Wang Gui-ye1   

  1. 1Department of Hematology, First Affiliated Hospital, Zhengzhou University, Zhengzhou  450052, Henan Province, China
    2Key Laboratory of Clinical Research for Henan University, Zhengzhou  450052, Henan Province, China
  • Received:2010-08-31 Revised:2010-11-01 Online:2011-02-05 Published:2011-02-05
  • Contact: Liu Yan-fang, Professor, Chief physician, Department of Hematology, First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, Henan Province, China; Key Laboratory of Clinical Research for Henan University, Zhengzhou 450052, Henan Province, China
  • About author:Pan Yang-qiong★, Studying for master’s degree, Department of Hematology, First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, Henan Province, China panyangqiong@126.com

PDF

319

Abstract:

BACKGROUND: The expression of TAp63 gene in bone marrow mononuclear cells derived from acute lymphoblastic leukemia (ALL) patients has been rarely reported.
OBJECTIVE: To investigate the expression and significance of TAp63 gene in bone marrow mononuclear cells of adult ALL.
METHODS: A total of 50 cases of ALL, including 32 cases of B-ALL and 18 cases of T-ALL, were enrolled. A total of 27 cases of adults without malignance disease served as control group. A total of 2-4 mL heparin anticoagulant bone marrow was collected. Bone marrow mononuclear cells were isolated using Ficoll liquid. TAp63 expression was examined by semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR).
RESULTS AND CONCLUSION: A total of 49 cases of 50 ALL cases expressed TAp63. The expression of TAp63 in ALL group was significantly higher than in control group (P < 0.05). The expression of TAp63 in B-ALL group was significantly higher than that of T-ALL group (P < 0.05). By sequential observation of TAp63 expression in different stages of ALL in 5 cases, TAp63 mRNA expression in patients who were in de novo and relapsed stages was significantly higher than that in complete remission stage. These results demonstrated that the expression of TAp63 in ALL patients was significantly higher than that of control group, especially in B-ALL.

CLC Number: